| Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. | |
| | |
MedLine Citation:
|
PMID: 18349315 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To retrospectively determine whether relative cerebral blood volume (CBV) measurements can be used to predict clinical outcome in patients with high-grade gliomas (HGGs) and low-grade gliomas (LGGs) and specifically whether patients who have gliomas with a high initial relative CBV have more rapid progression than those who have gliomas with a low relative CBV. MATERIALS AND METHODS: Approval for this retrospective HIPAA-compliant study was obtained from the Institutional Board of Research Associates, with waiver of informed consent. One hundred eighty-nine patients (122 male and 67 female patients; median age, 43 years; range, 4-80 years) were examined with dynamic susceptibility-weighted contrast material-enhanced perfusion magnetic resonance (MR) imaging and were followed up clinically with MR imaging (median follow-up, 334 days). Log-rank tests were used to evaluate the association between relative CBV and time to progression by using Kaplan-Meier curves. Binary logistic regression was used to determine whether age, sex, and relative CBV were associated with an adverse event (progressive disease or death). RESULTS: Values for the mean relative CBV for patients according to each clinical response were as follows: 1.41 +/- 0.13 (standard deviation) for complete response (n = 4), 2.36 +/- 1.78 for stable disease (n = 41), 4.84 +/- 3.32 for progressive disease (n = 130), and 3.82 +/- 1.93 for death (n = 14). Kaplan-Meier estimates of median time to progression in days indicated that patients with a relative CBV of less than 1.75 had a median time to progression of 3585 days, whereas patients with a relative CBV of more than 1.75 had a time to progression of 265 days. Age and relative CBV were also independent predictors for clinical outcome. CONCLUSION: Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging can be used to predict median time to progression in patients with gliomas, independent of pathologic findings. Patients who have HGGs and LGGs with a high relative CBV (>1.75) have a significantly more rapid time to progression than do patients who have gliomas with a low relative CBV. |
| | |
Authors:
|
Meng Law; Robert J Young; James S Babb; Nicole Peccerelli; Sophie Chheang; Michael L Gruber; Douglas C Miller; John G Golfinos; David Zagzag; Glyn Johnson |
Related Documents
:
|
15990015 - Assessment of the tumor microenvironment in cervix cancer using dynamic contrast enhanc... 10696895 - Diagnosing enteroceles using dynamic magnetic resonance imaging. 8234715 - Small hepatocellular carcinomas: two-phase dynamic incremental ct in detection and eval... 10701605 - Dynamic mr imaging of the pelvic floor in asymptomatic subjects. 693905 - Comparison of computed tomography, ultrasonography, and gallium-67 scanning in the eval... 1263905 - Improving radiology in surgery. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2008-03-18 |
Journal Detail:
|
Title: Radiology Volume: 247 ISSN: 1527-1315 ISO Abbreviation: Radiology Publication Date: 2008 May |
Date Detail:
|
Created Date: 2008-04-23 Completed Date: 2008-06-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401260 Medline TA: Radiology Country: United States |
Other Details:
|
Languages: eng Pagination: 490-8 Citation Subset: AIM; IM |
Copyright Information:
|
(c) RSNA, 2008. |
Affiliation:
|
Department of Radiology, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029, USA. Meng.law@mountsinai.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Area Under Curve Blood Volume Brain Neoplasms / pathology* Cerebrovascular Circulation* Child Child, Preschool Contrast Media Disease Progression Female Gadolinium DTPA / diagnostic use Glioma / pathology* Humans Logistic Models Magnetic Resonance Imaging / methods* Male Middle Aged Predictive Value of Tests Retrospective Studies Risk Factors Survival Rate |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA093992/CA/NCI NIH HHS; R01 CA100426/CA/NCI NIH HHS; R01 CA1111996/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; 80529-93-7/Gadolinium DTPA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Liver fat content and T2*: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0...
Next Document: Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advance...